The ubiquitin E3 ligase APC/CCdc20 mediates mitotic degradation of OGT

Juvenile hormone and BMP signaling modulate fat body cell fate during the transition of previtellogenic development to vitellogenesis

BACKGROUND

Insect fat body, a central tissue for nutrient storage, energy metabolism, and protein synthesis, degrades by apoptosis and autophagy during larval metamorphosis. After adult emergence, the fat body grows rapidly with cell proliferation and polyploidization during the previtellogenic period but ceases cell proliferation in the vitellogenic phase. So far, the regulatory mechanisms underlying fat body cell fate decisions in adulthood remain unknown.

RESULTS

Transcriptomic analysis of locust fat body revealed the enrichment of pathways associated with cell cycle, nuclear division, and DNA replication. Decapentaplegic (Dpp) was among the top of differentially expressed genes in the signaling cascades involved in regulating cell proliferation. Abundance of Dpp, phosphorylated Mad (p-Mad), and Medea increased during the previtellogenic stage and subsequently declined in the vitellogenic phase. Knockdown of Dpp, Mad, and Medea resulted in suppressed fat body cell proliferation, along with remarkably reduced cell number and blocked vitellogenin (Vg) expression in the fat body as well as consequent arrest of egg development. Mad/Medea complex bound to the promoters of cyclin B (CycB) and polo-like kinase 1 (Plk1) and stimulated their expression. Depletion of CycB and Plk1 caused the defective phenotypes resembling Dpp, Mad, and Medea knockdown. In the vitellogenic phase, the high levels of juvenile hormone (JH) promoted the degradation of Medea via fizzy-related protein (Fzr)-mediated ubiquitination, leading to inhibited cell proliferation. The results suggest that fat body cell proliferation in the previtellogenic development is promoted by the bone morphogenetic protein (BMP) signaling pathway, whereas high levels of JH in the vitellogenic stage antagonize BMP signaling for ceasing cell proliferation.

CONCLUSIONS

The findings provide novel insights into the regulation of fat body cell fate during the transition of previtellogenic growth to vitellogenic Vg synthesis for reproductive requirements.

Opportunities for Therapeutic Modulation of O-GlcNAc

O-Linked β-N-acetylglucosamine (O-GlcNAc) is an essential, dynamic monosaccharide post-translational modification (PTM) found on serine and threonine residues of thousands of nucleocytoplasmic proteins. The installation and removal of O-GlcNAc is controlled by a single pair of enzymes, O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA), respectively. Since its discovery four decades ago, O-GlcNAc has been found on diverse classes of proteins, playing important functional roles in many cellular processes. Dysregulation of O-GlcNAc homeostasis has been implicated in the pathogenesis of disease, including neurodegeneration, X-linked intellectual disability (XLID), cancer, diabetes, and immunological disorders. These foundational studies of O-GlcNAc in disease biology have motivated efforts to target O-GlcNAc therapeutically, with multiple clinical candidates under evaluation. In this review, we describe the characterization and biochemistry of OGT and OGA, cellular O-GlcNAc regulation, development of OGT and OGA inhibitors, O-GlcNAc in pathophysiology, clinical progress of O-GlcNAc modulators, and emerging opportunities for targeting O-GlcNAc. This comprehensive resource should motivate further study into O-GlcNAc function and inspire strategies for therapeutic modulation of O-GlcNAc.

14-3-3ε augments OGT stability by binding with S20-phosphorylated OGT

The relationship between O-linked N-acetylglucosamine (O-GlcNAc) transferase (OGT) and mitosis is intertwined. Besides the numerous mitotic OGT substrates that have been identified, OGT itself is also a target of the mitotic machinery. Previously, our investigations have shown that Checkpoint kinase 1 (Chk1) phosphorylates OGT at Ser-20 to increase OGT levels during cytokinesis, suggesting that OGT levels oscillate as mitosis progresses. Herein we studied its underlying mechanism. We set out from an R17C mutation of OGT, which is a uterine carcinoma mutation in The Cancer Genome Atlas. We found that R17C abolishes the S20 phosphorylation of OGT, as it lies in the Chk1 phosphorylating consensus motif. Consistent with our previous report that pSer-20 is essential for OGT level increases during cytokinesis, we further demonstrate that the R17C mutation renders OGT less stable, decreases vimentin phosphorylation levels and results in cytokinesis defects. Based on bioinformatic predictions, pSer-20 renders OGT more likely to interact with 14-3-3 proteins, the phospho-binding signal adaptor/scaffold protein family. By screening the seven isoforms of 14-3-3 family, we show that 14-3-3ε specifically associates with Ser-20-phosphorylated OGT. Moreover, we studied the R17C and S20A mutations in xenograft models and demonstrated that they both inhibit uterine carcinoma compared to wild-type OGT, probably due to less cellular reproduction. Our work is a sequel of our previous report on pS20 of OGT and is in line with the notion that OGT is intricately regulated by the mitotic network.